Source-grounded facts extracted from TG THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TG THERAPEUTICS, INC. shareholders rejected Advisory vote to approve the compensation of the Company’s named executive officers at the 2026-06-11 meeting.
“Proposal 3 The advisory vote to approve the compensation of the Company’s named executive officers was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 31,905,837 48,858,169 668,903 31,570,505”
TG THERAPEUTICS, INC. shareholders approved Ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
“Proposal 2 The vote with respect to the ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 112,329,330 531,758 142,326 --”
TG THERAPEUTICS, INC. shareholders approved Election of six directors to hold office until the 2027 annual meeting at the 2026-06-11 meeting.
“Proposal 1 The votes with respect to the election of the six directors to hold office until the 2027 annual meeting were as follows: Director Votes For % Voted For Votes Withheld % Voted Withheld Broker Non-Votes Michael S. Weiss 72,172,630 88.63% 9,260,279 11.37% 31,570,505 Laurence N. Charney 68,135,448 83.67% 13,297,461 16.33% 31,570,505 Yann Echelard 64,110,661 78.73% 17,322,248 21.27% 31,570,505 Kenneth Hoberman 53,354,717 65.52% 28,078,192 34.48% 31,570,505 Daniel Hume 63,979,535 78.57% 17,453,374 21.43% 31,570,505 Sagar Lonial, MD 44,666,544 54.85% 36,766,365 45.15% 31,570,505”
TG THERAPEUTICS, INC. updated its the three months ended March 31, 2026 guidance (raised).
“On May 6, 2026, the Company issued a press release announcing results of operations for the three months ended March 31, 2026.”
TG THERAPEUTICS, INC. incurred term loan of $750 million with Blue Owl Capital Corporation at an applicable margin plus, at the Borrower’s option, either (a) a base rate dete maturing March 18, 2031.
“the Borrower established (i) a $750 million term loan facility (the “2026 Term Loan”), which was borrowed in full on the Closing Date”
TG THERAPEUTICS, INC. amended First Amendment with Blue Owl Capital Corporation, as administrative agent, and the lenders party thereto valued at $750 million term loan facility (effective 2026-03-18).
“On March 18, 2026 (the “Closing Date”), the Company (the “Borrower”) entered into the first amendment agreement, dated as of the Closing Date (the “First Amendment”), by and among the Borrower, certain subsidiaries of the Borrower, as guarantors, the lenders party thereto and Blue Owl Capital Corporation, as administrative agent (the “Administrative Agent”), which amends the financing agreement, dated as of August 2, 2024”
TG THERAPEUTICS, INC. updated its the three months ended March 31, 2024 guidance (raised).
“On May 1, 2024, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results of operations for the three months ended March 31, 2024.”
TG THERAPEUTICS, INC. updated its the fourth quarter and year ended December 31, 2023 guidance (raised).
“On February 28, 2024, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results of operations for the three and twelve months ended December 31, 2023.”
TG THERAPEUTICS, INC. entered into License Agreement with Precision BioSciences, Inc. valued at $7.5 million (effective 2024-01-07).
“On January 7, 2024, TG Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary, TG Cell Therapy, Inc., entered into a License Agreement (the “License Agreement”) with Precision BioSciences, Inc. (“Precision”), pursuant to which Precision granted the Company certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize Precision’s allogeneic CAR T therapy azercabtagene zapreleucel (“azer-cel”) for the treatment of autoimmune and other non-oncology diseases and conditions (collectively, the “Field”).”
TG THERAPEUTICS, INC. reported three and nine months ended September 30, 2023 results: revenue $165.8 million, net income $113.9 million and $27.1 million.
“Third quarter 2023 total net revenue of $165.8 million”
TG THERAPEUTICS, INC. reported six months ended June 30, 2023 results: revenue $23.8 million, net income $86.8 million.
“Product Revenue, Net: Product revenue, net was approximately $16.0 million and $23.8 million for the three and six months ended June 30, 2023, compared to $0.6 million and $2.5 million for the three and six months ended June 30, 2022. Product revenue, net for the three and six months ended June 30, 2023, consisted of net product sales of BRIUMVI in the U.S., which was commercially launched in late January 2023. Product revenue, net for the three and six months ended June 30, 2022, consisted of net product sales of UKONIQTM (umbralisib), which was withdrawn from the U.S. market in May of 2022. ● R&D Expenses: Total research and development (R&D) expense was $28.1 million and $44.0 million for the three and six months ended June 30, 2023, compared to $26.9 million and $74.9 million for the three and six months ended June 30, 2022. The decrease in R&D expense during the six months ended June 30, 2023 was primarily attributable to reduced manufacturing expense and clinical trial related”
TG THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: revenue $16.0 million, net income $47.6 million.
“Product Revenue, Net: Product revenue, net was approximately $16.0 million and $23.8 million for the three and six months ended June 30, 2023, compared to $0.6 million and $2.5 million for the three and six months ended June 30, 2022. Product revenue, net for the three and six months ended June 30, 2023, consisted of net product sales of BRIUMVI in the U.S., which was commercially launched in late January 2023. Product revenue, net for the three and six months ended June 30, 2022, consisted of net product sales of UKONIQTM (umbralisib), which was withdrawn from the U.S. market in May of 2022. ● R&D Expenses: Total research and development (R&D) expense was $28.1 million and $44.0 million for the three and six months ended June 30, 2023, compared to $26.9 million and $74.9 million for the three and six months ended June 30, 2022. The decrease in R&D expense during the six months ended June 30, 2023 was primarily attributable to reduced manufacturing expense and clinical trial related”
TG THERAPEUTICS, INC. entered into Commercialization Agreement with Neuraxpharm Pharmaceuticals, S.L. valued at Total deal valued at up to $645 million in upfront and milestone payments, including $140 million up (effective 2023-07-28).
“On July 28, 2023, TG Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary TG Biologics, Inc. entered into a Commercialization Agreement (the “Agreement”) with Neuraxpharm Pharmaceuticals, S.L. (“Neuraxpharm”), pursuant to which the Company granted Neuraxpharm an exclusive license to commercialize BRIUMVI ® (ublituximab) for relapsing forms of multiple sclerosis (“RMS”) in Europe and certain other territories outside the United States (collectively, the “Territory”), excluding Canada and Mexico, which are retained by the Company, and certain Asian countries previously partnered. Under the terms of the Agreement, Neuraxpharm is obligated to use commercially reasonable efforts to launch and commercialize BRIUMVI in the Territory, including maintaining current marketing authorizations, and obtaining additional marketing authorizations for BRIUMVI in the Territory, in accordance with a commercialization plan. The Company retains an option to buy back all rights under the Agr”
TG THERAPEUTICS, INC. reported the twelve months ended December 31, 2022 results: revenue $2.6 million, net income $198.3 million.
“Product Revenue, net: Product revenue, net was approximately zero and $2.6 million for the three and twelve months ended December 31, 2022. Net product revenues during the year represent U.S. sales of UKONIQ, which received approval in February of 2021 and was withdrawn from the U.S. market effective May 31, 2022. · R&D Expenses: Total research and development (R&D) expense was $29.6 million and $125.4 million for the three and twelve months ended December 31, 2022, compared to $62.6 million and $222.6 million for the three and twelve months ended December 31, 2021. The decrease in R&D expense is primarily attributable to reduced clinical trial related expenses, license milestones and manufacturing expense, decreased headcount and lower fees paid to consultants and outside service providers, as well as a decrease in non-cash compensation R&D expense during the twelve months ended December 31, 2022 over the comparable period in 2021. · SG&A Expenses: Total selling, general and administr”
TG THERAPEUTICS, INC. reported the three months ended December 31, 2022 results: revenue approximately zero, net income $53.0 million.
“Product Revenue, net: Product revenue, net was approximately zero and $2.6 million for the three and twelve months ended December 31, 2022. Net product revenues during the year represent U.S. sales of UKONIQ, which received approval in February of 2021 and was withdrawn from the U.S. market effective May 31, 2022. · R&D Expenses: Total research and development (R&D) expense was $29.6 million and $125.4 million for the three and twelve months ended December 31, 2022, compared to $62.6 million and $222.6 million for the three and twelve months ended December 31, 2021. The decrease in R&D expense is primarily attributable to reduced clinical trial related expenses, license milestones and manufacturing expense, decreased headcount and lower fees paid to consultants and outside service providers, as well as a decrease in non-cash compensation R&D expense during the twelve months ended December 31, 2022 over the comparable period in 2021. · SG&A Expenses: Total selling, general and administr”
TG THERAPEUTICS, INC. reported nine months ended September 30, 2022 results: net income $145.3 million.
“Net loss was $35.8 million and $145.3 million for the three and nine months ended September 30, 2022”
TG THERAPEUTICS, INC. reported three months ended September 30, 2022 results: net income $35.8 million.
“Net loss was $35.8 million and $145.3 million for the three and nine months ended September 30, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.